Thanks to our donors’s support, we have raised sufficient fund to cover for our operation, production, publicity, and conference attendance in 2025. In addition to staying as an active patient advocate voice at ASCO, Hear2Care has also engaged with MASCC, PCORI, FDA Foundation, with visibility across target disease areas and communities. In April 2025, we received USPTO’s approval of our trademark HEAR2CARE, in the International classes 009 and 041 (#98246752).
Patient Education that immigrants can understand
By the end of 2025, Hear2Care has published 23 podcast episodes on Spotify, where our audiences have increased 110% and followers increased by 200%. The published contents covered the topics of Asian American physical and mental health, cancer supportive care for Lymphoma and GI Cancers. They are available as customizable playlists:
These podcasts are also available on Apple Podcast:
Engagement with local communities
With the help of our advisory board member Ms Kristi Heim, our Founder Dr. Tingting Zhang was featured on Chinese Radio Seattle’s “American Stories” to highlight Asian Americans’ struggles with accessing quality cancer care and prevention.
We have been actively engaged with GI cancer patient groups and supportive care research communities to design and implement optimized engagement approaches with patients with Limited English Proficiency.
Advocacy for inclusive cancer care delivery
In Febuary 2025, Dr Zhang presented the talk on “Addressing Cultural Diversity in Global Cancer Care” at the inaugural Transcultural Oncology webinar series at African Diaspora Cancer Network, and received additional invitations to present “Transcultural Cancer Care Delivery” at the September Grand Rounds of Hem/Onc department at Weill Cornell New York Presbyterian, as well as the October Coffee Talks of The Cancer Survivorship Provider Network.
Hear2Care was also an author as well as an endorser for the Patient Charter for Hepatocellular carcinoma (HCC) as an active member of the International Liver Cancer Movement (ILCM). Our Vietnamese speaking volunteer signed up from Microsoft helped to make ILCM’s HCC awareness poster tool available in Vietnamese in collaboration with APAC Liver Disease Alliance.
In 2025, we examined potential underestimation of gastrointestinal cancer mortality among Asian Americans related to incomplete capture of American citizens’ deaths occurring outside the United States due to medical tourism (Salmon Bias Effect). Peer-review feedback on the initial manuscript highlighted opportunities to strengthen the methodology and positioning within the epidemiologic literature. A revised version is in development, and the current preprint remains publicly available on MedXiv.
Advocacy for awareness and management of cancer treatment toxicities
Dr Zhang proposed and chaired the “Partnering with patients in managing chronic toxicities of cancer and its treatments” workshop at MASCC 2025 annual meeting in Seattle and her workshop presentation on the utilization of pharmacovigilance data in guiding cancer supportive care research led to the engagement with the IMEDS team of Reagan-Udall Foundation of FDA, with help from the project interface team at FDA’s Oncology Center of Excellence. Hear2Care led a number of cancer patient organizations and researchers (PCDI/pan-breast, EFGRResister/Lung, ACE, HESI, LBC, IBC, etc) to launch an initiative for patient centered utilization of federal pharmacovigilance resources. This project is now a proposed project at the MASCC Emerging Toxicity SG, and the topic is to be presented at ASCO PallOnc CoP meeting in June 2026.
Photo credit: Dr Gitte H Joergensen (Lobular Breast Cancer Alliance Inc)
Advocacy for Patient Centered Clinical Research
In August 2025, A NCI grant for supportive care research of elderly lung cancer patients was approved for which Dr Zhang served as a member of the Patient and Caregiver Advisory Board. We are encouraged by another grant resubmission to PCORI from our collaborator at MSKCC. We will continue work on supporting additional clinical researchers to improve care access of patients with language barriers.
In September 2025, Dr Zhang was selected to serve as an advisory panelist from 2025 to 2028 for the newly established CER advisory panel at PCORI, a federal funded research institute that funds patient-centered comparative clinical effectiveness research (CER).
Thank you again for your support and we look forward to your continued support in a fruitful 2026!
Hear2Care is a US 501c3 nonprofit based in the State of Washington.
You can find Hear2Care on your company intranet’s corporate responsibility page (through Benevity) by searching for “Hear2Care” or Benevity ID (840-933638070) if you are interested in supporting our cause!
Leave a Reply